Allergan Launches Generic Version of INVEGA® (paliperidone)

DUBLIN, Sept. 25, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has launched a generic version of Janssen's INVEGA^® (paliperidone extended-release tablets) in the U.S.  Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA^®, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.

Logo- http://photos.prnewswire.com/prnh/20150612/222796LOGO

"This launch reinforces Allergan's commitment to developing, manufacturing and bringing to market high-quality, affordable versions of challenging products like INVEGA^®, benefiting patients and reducing healthcare costs," said Robert Stewart, Allergan's Executive Vice President & President, Generics and Global Operations.

INVEGA^® extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age).

For the 12 months ended July 31, 2015, INVEGA^® had total U.S. brand sales of approximately $612 million, according to IMS Health data.

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statements 
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:
Allergan:
Investors:
Lisa DeFrancesco 
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc

Related Links

http://www.allergan.com